Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1984 2
1987 1
1988 1
1989 2
1990 1
1992 3
1993 2
1994 2
1995 3
1996 4
1997 1
1998 4
1999 1
2000 5
2001 1
2002 3
2003 2
2004 7
2005 3
2006 5
2007 2
2008 1
2009 3
2010 1
2011 2
2012 2
2013 2
2014 4
2015 3
2016 2
2017 2
2018 2
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Results by year

Filters applied: . Clear all
Page 1
Antibody-enzyme fusion proteins for cancer therapy.
Andrady C, Sharma SK, Chester KA. Andrady C, et al. Among authors: chester ka. Immunotherapy. 2011 Feb;3(2):193-211. doi: 10.2217/imt.10.90. Immunotherapy. 2011. PMID: 21322759 Review.
Antibody-drug conjugates - a perfect synergy.
Adair JR, Howard PW, Hartley JA, Williams DG, Chester KA. Adair JR, et al. Among authors: chester ka. Expert Opin Biol Ther. 2012 Sep;12(9):1191-206. doi: 10.1517/14712598.2012.693473. Epub 2012 Jun 1. Expert Opin Biol Ther. 2012. PMID: 22650648 Review.
Recombinant anti-carcinoembryonic antigen antibodies for targeting cancer.
Chester KA, Mayer A, Bhatia J, Robson L, Spencer DI, Cooke SP, Flynn AA, Sharma SK, Boxer G, Pedley RB, Begent RH. Chester KA, et al. Cancer Chemother Pharmacol. 2000;46 Suppl:S8-12. doi: 10.1007/pl00014055. Cancer Chemother Pharmacol. 2000. PMID: 10950140 Review.
Clinical issues in antibody design.
Chester KA, Hawkins RE. Chester KA, et al. Trends Biotechnol. 1995 Aug;13(8):294-300. doi: 10.1016/S0167-7799(00)88968-4. Trends Biotechnol. 1995. PMID: 7662305 Review.
Homogeneous bispecifics by disulfide bridging.
Hull EA, Livanos M, Miranda E, Smith ME, Chester KA, Baker JR. Hull EA, et al. Among authors: chester ka. Bioconjug Chem. 2014 Aug 20;25(8):1395-401. doi: 10.1021/bc5002467. Epub 2014 Aug 1. Bioconjug Chem. 2014. PMID: 25033024 Free PMC article.
Taking engineered anti-CEA antibodies to the clinic.
Mayer A, Chester KA, Flynn AA, Begent RH. Mayer A, et al. Among authors: chester ka. J Immunol Methods. 1999 Dec 10;231(1-2):261-73. doi: 10.1016/s0022-1759(99)00162-3. J Immunol Methods. 1999. PMID: 10648943 Review.
Antibody-directed enzyme-prodrug therapy.
Pedley RB, Sharma SK, Hawkins RE, Chester KA. Pedley RB, et al. Among authors: chester ka. Methods Mol Med. 2004;90:491-514. doi: 10.1385/1-59259-429-8:491. Methods Mol Med. 2004. PMID: 14657581 No abstract available.
Clinical applications of phage-derived sFvs and sFv fusion proteins.
Chester KA, Bhatia J, Boxer G, Cooke SP, Flynn AA, Huhalov A, Mayer A, Pedley RB, Robson L, Sharma SK, Spencer DI, Begent RH. Chester KA, et al. Dis Markers. 2000;16(1-2):53-62. doi: 10.1155/2000/672706. Dis Markers. 2000. PMID: 11360829 Free PMC article. Review.
From laboratory to Phase I/II cancer trials with recombinant biotherapeutics.
Tolner B, Smith L, Hillyer T, Bhatia J, Beckett P, Robson L, Sharma SK, Griffin N, Vervecken W, Contreras R, Pedley RB, Begent RH, Chester KA. Tolner B, et al. Among authors: chester ka. Eur J Cancer. 2007 Nov;43(17):2515-22. doi: 10.1016/j.ejca.2007.08.027. Epub 2007 Oct 22. Eur J Cancer. 2007. PMID: 17933516 Review.
79 results